Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands.
Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
PLoS One. 2014 Mar 18;9(3):e91396. doi: 10.1371/journal.pone.0091396. eCollection 2014.
The aim of this study was to compare the current screening methods and to evaluate confirmation tests for phenotypic plasmidal AmpC (pAmpC) detection.
For this evaluation we used 503 Enterobacteriaceae from 18 Dutch hospitals and 21 isolates previously confirmed to be pAmpC positive. All isolates were divided into three groups: isolates with 1) reduced susceptibility to ceftazidime and/or cefotaxime; 2) reduced susceptibility to cefoxitin; 3) reduced susceptibility to ceftazidime and/or cefotaxime combined with reduced susceptibility to cefoxitin. Two disk-based tests, with cloxacillin or boronic acid as inhibitor, and Etest with cefotetan-cefotetan/cloxacillin were used for phenotypic AmpC confirmation. Finally, presence of pAmpC genes was tested by multiplex and singleplex PCR.
We identified 13 pAmpC producing Enterobacteriaceae isolates among the 503 isolates (2.6%): 9 CMY-2, 3 DHA-1 and 1 ACC-1 type in E. coli isolates. The sensitivity and specificity of reduced susceptibility to ceftazidime and/or cefotaxime in combination with cefoxitin was 97% (33/34) and 90% (289/322) respectively. The disk-based test with cloxacillin showed the best performance as phenotypic confirmation method for AmpC production.
For routine phenotypic detection of pAmpC the screening for reduced susceptibility to third generation cephalosporins combined with reduced susceptibility to cefoxitin is recommended. Confirmation via a combination disk diffusion test using cloxacillin is the best phenotypic option. The prevalence found is worrisome, since, due to their plasmidal location, pAmpC genes may spread further and increase in prevalence.
本研究旨在比较目前的筛选方法,并评估表型质粒型 AmpC(pAmpC)检测的确认试验。
为了进行评估,我们使用了来自 18 家荷兰医院的 503 株肠杆菌科细菌和 21 株先前确认为 pAmpC 阳性的分离株。所有分离株分为三组:1)对头孢他啶和/或头孢噻肟的敏感性降低;2)对头孢西丁的敏感性降低;3)对头孢他啶和/或头孢噻肟的敏感性降低,同时对头孢西丁的敏感性降低。使用两种以氯唑西林或硼酸为抑制剂的纸片扩散试验,以及以头孢替坦-头孢替坦/氯唑西林为抑制剂的 Etest 进行表型 AmpC 确认。最后,通过多重和单重 PCR 检测 pAmpC 基因的存在。
我们在 503 株分离株中发现了 13 株产 pAmpC 的肠杆菌科细菌(2.6%):9 株大肠埃希菌的 CMY-2、3 株阴沟肠杆菌的 DHA-1 和 1 株产气肠杆菌的 ACC-1 型。头孢他啶和/或头孢噻肟联合头孢西丁敏感性降低的敏感性和特异性分别为 97%(33/34)和 90%(289/322)。以氯唑西林为抑制剂的纸片扩散试验作为 AmpC 产生的表型确认方法表现最佳。
对于 pAmpC 的常规表型检测,建议筛选第三代头孢菌素敏感性降低并伴有头孢西丁敏感性降低。使用氯唑西林联合的组合纸片扩散试验进行确证是最佳的表型选择。发现的流行率令人担忧,因为由于其质粒位置,pAmpC 基因可能会进一步传播并增加流行率。